Text and Data Mining valid from 2019-10-11
Received: 1 August 2019
Accepted: 23 September 2019
First Online: 11 October 2019
Ethics approval and consent to participate
: This study has obtained appropriate institutional review board approval for analysis of deidentified and limited data sets which waived the need for individual patient informed consent.
: Not applicable.
: SRF, AK, RBL, and RJN are employees and shareholders of Guardant Health, Inc. OZ and GT are employees of NovellusDx. JJL received honoraria from or served as a consultant for Chugai and Boehringer-Ingelheim and received institutional research funding from Loxo Oncology. ATS has served as a compensated consultant or received honoraria from Pfizer, Novartis, Genentech/Roche, Ariad/Takeda, Ignyta, LOXO, Bayer, Chugai, Blueprint Medicines, KSQ Therapeutics, Daiichi Sankyo, EMD Serono, Taiho Pharmaceutical, TP Therapeutics, Foundation Medicine, Guardant, Natera, Servier, and Syros; has received institutional research funding from Pfizer, Novartis, Roche/Genentech, Ariad, Ignyta, and TP Therapeutics; and has received travel support from Pfizer and Roche/Genentech. The remaining authors do not report relevant competing interests.